PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16757730-7	2006	Candesartan treatment from the onset of obstruction attenuated the reduction in GFR (3.1 +/- 0.4 vs. 1.7 +/- 0.3 ml.min(-1).kg(-1)) and partially prevented the reduction in the expression of AQP2 (66 +/- 21 vs. 13 +/- 2%, n = 7; P < 0.05), NaPi-2 (84 +/- 6 vs. 57 +/- 10%, n = 7; P < 0.05), and NKCC2 (89 +/- 12 vs. 46% +/- 11, n = 7; P < 0.05).	candesartan	0-11	aquaporin 2	Rattus norvegicus	191-195	
19776175-6	2009	Candesartan treatment significantly reversed the increases in both AQP2 and p-AQP2 expression and targeting.	candesartan	0-11	aquaporin 2	Rattus norvegicus	67-71	
19776175-6	2009	Candesartan treatment significantly reversed the increases in both AQP2 and p-AQP2 expression and targeting.	candesartan	0-11	aquaporin 2	Rattus norvegicus	78-82	
18417538-11	2008	Candesartan-treated DM rats had slightly higher AQP2 in IM (46%, P < 0.05) vs. control rats.	candesartan	0-11	aquaporin 2	Rattus norvegicus	48-52	
17032940-11	2007	In conclusion, candesartan prevents or attenuates the reduction in RBF, GFR and dysregulation of AQP2 and Na-K-ATPase in response to congenital PUUO in rats, suggesting that AT1R blockade may protect the neonatally obstructed kidney against development of obstructive nephropathy.	candesartan	15-26	aquaporin 2	Rattus norvegicus	97-101	
16896188-7	2007	ANG II-induced AQP2 targeting was blocked by 10(-5) M candesartan.	candesartan	54-65	aquaporin 2	Rattus norvegicus	15-19	
16757730-10	2006	In conclusion, candesartan prevents dysregulation of AQP2, sodium transporters, and development of polyuria seen in BUO.	candesartan	15-26	aquaporin 2	Rattus norvegicus	53-57	
15585668-8	2005	Semiquantitative immunoblotting revealed significantly decreased expression of medullary aquaporin-2 (AQP2) and AQP2 phosphorylated in the PKA phosphorylation consensus site Ser-256 (p-AQP2) in response to DDAVP and candesartan cotreatment compared with DDAVP treatment alone.	candesartan	216-227	aquaporin 2	Rattus norvegicus	89-100	
15585668-8	2005	Semiquantitative immunoblotting revealed significantly decreased expression of medullary aquaporin-2 (AQP2) and AQP2 phosphorylated in the PKA phosphorylation consensus site Ser-256 (p-AQP2) in response to DDAVP and candesartan cotreatment compared with DDAVP treatment alone.	candesartan	216-227	aquaporin 2	Rattus norvegicus	102-106	
15585668-8	2005	Semiquantitative immunoblotting revealed significantly decreased expression of medullary aquaporin-2 (AQP2) and AQP2 phosphorylated in the PKA phosphorylation consensus site Ser-256 (p-AQP2) in response to DDAVP and candesartan cotreatment compared with DDAVP treatment alone.	candesartan	216-227	aquaporin 2	Rattus norvegicus	112-116	
15585668-8	2005	Semiquantitative immunoblotting revealed significantly decreased expression of medullary aquaporin-2 (AQP2) and AQP2 phosphorylated in the PKA phosphorylation consensus site Ser-256 (p-AQP2) in response to DDAVP and candesartan cotreatment compared with DDAVP treatment alone.	candesartan	216-227	aquaporin 2	Rattus norvegicus	112-116